Skip to main content
Erschienen in: Endocrine 3/2018

06.01.2018 | Original Article

Suspected ontogeny of a recently described hypo-androgenic PCOS-like phenotype with advancing age

verfasst von: Norbert Gleicher, Vitaly A. Kushnir, Sarah K. Darmon, Qi Wang, Lin Zhang, David F. Albertini, David H. Barad

Erschienen in: Endocrine | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

A recent report described a new PCOS-like phenotype in lean older infertile women, and was characterized by high age-specific anti-Müllerian hormone (AMH) but hypo- rather than the expected hyper-androgenism. The hypo-androgenism was, furthermore, characterized of, likely, adrenal origin and autoimmune etiology.

Patients and methods

We extracted data on 708 consecutive infertility patients, and separated them into three age-strata, <35, 36–42, and >42 years. In each stratum, we investigated how levels of anti-Müllerian hormone (AMH) and testosterone (T) interrelate between high-AMH (AMH ≥ 75th quantile) and normal AMH (25th–75th quantile) and low-T (total testosterone ≤19.0 ng/dL), normal-T (19.0–29.0 ng/dL) and high-T (>29.0 ng/dL). High-AMH cycles were presumed to reflect PCOS-like patients. Routine in vitro fertilization (IVF) cycle outcomes and clinical phenotypes of patients were then compared between groups with AMH and T as statistical variables.

Results

This hypo-androgenic PCOS-like phenotype already exists in age stratum <35 years. It appears to arise from a lean, at very young ages hyper-androgenic PCOS phenotype that develops in comparison to controls (likely autoimmune-induced) insufficiency of the adrenal zona reticularis (low-T and low-DHEAS) and zona fasciculata (low-C), and is characterized by frequent evidence of autoimmunity. A degree of adrenal insufficiency, thus, concomitantly appears to affect adrenal androgen and, to lesser degrees, glucocorticoid production (mineralocorticoids were not investigated).

Conclusions

Here investigated new PCOS-like phenotype demonstrates features compatible with what under Rotterdam criteria has been referred to as PCOS phenotype-D. If confirmed, the observation that the ontogeny of this phenotype already at young ages is, likely, driven by adrenal autoimmunity, supports the position of the androgen excess and PCOS society that the etiology of phenotype-D differs from that of classical hyper-androgenic PCOS of mostly ovarian etiology.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat R. Azziz, K.S. Woods, R. Reyna, T.J. Key, E.S. Knochenhauer, B.O. Yildiz, The prevalence and features of the polycystic ovary syndrome in an unselected patient population. J. Clin. Endocrinol. Metab. 89, 2745–2749 (2004)CrossRef R. Azziz, K.S. Woods, R. Reyna, T.J. Key, E.S. Knochenhauer, B.O. Yildiz, The prevalence and features of the polycystic ovary syndrome in an unselected patient population. J. Clin. Endocrinol. Metab. 89, 2745–2749 (2004)CrossRef
2.
Zurück zum Zitat D. Dewailly, P. Pigny, B. Soudan, S. Catteau-Jonard, C. Decanter, E. Poncelet, A. Duhamel, Reconciling the defnition of polycystc ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentration aggregate with the markers of hyperandrogenism. J. Clin. Endocrinol. Metab. 95, 4399–4405 (2010)CrossRef D. Dewailly, P. Pigny, B. Soudan, S. Catteau-Jonard, C. Decanter, E. Poncelet, A. Duhamel, Reconciling the defnition of polycystc ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentration aggregate with the markers of hyperandrogenism. J. Clin. Endocrinol. Metab. 95, 4399–4405 (2010)CrossRef
3.
Zurück zum Zitat S. Iliodromiti, T.W. Lelsey, R.A. Anderson, S.M. Nelson, Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J. Clin. Endocrinol. Metab. 98, 3332–3340 (2013)CrossRef S. Iliodromiti, T.W. Lelsey, R.A. Anderson, S.M. Nelson, Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J. Clin. Endocrinol. Metab. 98, 3332–3340 (2013)CrossRef
4.
Zurück zum Zitat J.K. Zawadski, A. Dunaif, Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. in Polycystic Ovary Syndrome, eds. by A. Dunaif, J.R. Givens, F.P. Haseltine, G.R. Merriam (Blackwell Scientific, Boston, MA, 1992), pp. 377–384 J.K. Zawadski, A. Dunaif, Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. in Polycystic Ovary Syndrome, eds. by A. Dunaif, J.R. Givens, F.P. Haseltine, G.R. Merriam (Blackwell Scientific, Boston, MA, 1992), pp. 377–384
5.
Zurück zum Zitat The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19, 41–47 (2004)CrossRef The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19, 41–47 (2004)CrossRef
6.
Zurück zum Zitat R. Azziz, E. Carmine, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, W. Futterweit et al., Position statement: criteria for defining polycystic ovary syndrome as apredominantly hyperandrogenic syndrome. An Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 91, 4237–4245 (2006)CrossRef R. Azziz, E. Carmine, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, W. Futterweit et al., Position statement: criteria for defining polycystic ovary syndrome as apredominantly hyperandrogenic syndrome. An Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 91, 4237–4245 (2006)CrossRef
7.
Zurück zum Zitat C.R. McCartney, J. Marshall, Clinical practice. Polycystic ovary syndrome. N. Engl. J. Med. 375, 54–64 (2016)CrossRef C.R. McCartney, J. Marshall, Clinical practice. Polycystic ovary syndrome. N. Engl. J. Med. 375, 54–64 (2016)CrossRef
8.
Zurück zum Zitat D. Lizneva, L. Sururina, W. Walker, S. Brakta, L. Gavrilova-Jordan, R. Azziz, Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil. Steril. 106, 6–15 (2016)CrossRef D. Lizneva, L. Sururina, W. Walker, S. Brakta, L. Gavrilova-Jordan, R. Azziz, Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil. Steril. 106, 6–15 (2016)CrossRef
9.
Zurück zum Zitat R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, W. Futterweit et al., The Androgen excess and PCOS Society criteria for the polycysticovary syndrome: the complete task force report. Fertil. Steril. 91, 456–488 (2009)CrossRef R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, W. Futterweit et al., The Androgen excess and PCOS Society criteria for the polycysticovary syndrome: the complete task force report. Fertil. Steril. 91, 456–488 (2009)CrossRef
10.
Zurück zum Zitat N. Gleicher, A. Kim, A. Weghofer, D.H. Barad, Toward a better understanding of functional ovarian reserve: AMH (AMHo) and FSH (FSHo) hormone ratios per retrieved oocyte. J. Clin. Endocrinol. Metab. 97, 995–1004 (2012)CrossRef N. Gleicher, A. Kim, A. Weghofer, D.H. Barad, Toward a better understanding of functional ovarian reserve: AMH (AMHo) and FSH (FSHo) hormone ratios per retrieved oocyte. J. Clin. Endocrinol. Metab. 97, 995–1004 (2012)CrossRef
11.
Zurück zum Zitat N. Gleicher, A. Kim, V. Kushnir, A. Weghofer, A. Shohat-Tal, E. Lazzaroni, H.-J. Lee, D.H. Barad, Clinical relevance of combined FSH and AMH observations in infertile women. J. Clin. Endocrinol. Metab. 98, 2136–2145 (2013)CrossRef N. Gleicher, A. Kim, V. Kushnir, A. Weghofer, A. Shohat-Tal, E. Lazzaroni, H.-J. Lee, D.H. Barad, Clinical relevance of combined FSH and AMH observations in infertile women. J. Clin. Endocrinol. Metab. 98, 2136–2145 (2013)CrossRef
12.
Zurück zum Zitat N. Gleicher, V.A. Kushnir, S.K. Darmon, A. Weghofer, Q. Wang, L. Zhang, D.F. Albertini, D. Barad, New PCOS-like phenotype in older women of likely autoimmune adrenal etiology with high AMH but low androgens. 2016. J. Steroid Biochem. Reprod. Biol. 167, 144–152 (2017)CrossRef N. Gleicher, V.A. Kushnir, S.K. Darmon, A. Weghofer, Q. Wang, L. Zhang, D.F. Albertini, D. Barad, New PCOS-like phenotype in older women of likely autoimmune adrenal etiology with high AMH but low androgens. 2016. J. Steroid Biochem. Reprod. Biol. 167, 144–152 (2017)CrossRef
13.
Zurück zum Zitat D.M. Otterness, R. Weinshilboum, Human dehydroepiandrosterone sulfotransferase: molecular cloning of cDNA and genomic DNA. Chem. Biol. Interact. 92, 145–159 (1994)CrossRef D.M. Otterness, R. Weinshilboum, Human dehydroepiandrosterone sulfotransferase: molecular cloning of cDNA and genomic DNA. Chem. Biol. Interact. 92, 145–159 (1994)CrossRef
14.
Zurück zum Zitat S.R. Bornstein, B. Allolio, W. Arlt, A. Barthel, A. Son-Wauchope, G.D. Hammer, E.S. Husebye, D.P. Merke, M.H. Murad, C.A. Stratakis, D.J. Torpy, Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 101, 364–389 (2016)CrossRef S.R. Bornstein, B. Allolio, W. Arlt, A. Barthel, A. Son-Wauchope, G.D. Hammer, E.S. Husebye, D.P. Merke, M.H. Murad, C.A. Stratakis, D.J. Torpy, Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 101, 364–389 (2016)CrossRef
15.
Zurück zum Zitat V.A. Kushnir, N. Halevy, D.H. Barad, D.F. Albertini, N. Gleicher, Relative importance of androgen changes with aging among non-obese women with polycstic ovary syndrome. J. Ovarian Res. 8, 45 (2015)CrossRef V.A. Kushnir, N. Halevy, D.H. Barad, D.F. Albertini, N. Gleicher, Relative importance of androgen changes with aging among non-obese women with polycstic ovary syndrome. J. Ovarian Res. 8, 45 (2015)CrossRef
16.
Zurück zum Zitat A. Weghofer, A. Kim, D.H. Barad, N. Gleicher, The impact of androgen metabolism and FMR1 genotypes on pregnancy potential in women with dehydroepiandrosterone (DHEA) supplementation. Hum. Reprod. 27, 3287–3293 (2012)CrossRef A. Weghofer, A. Kim, D.H. Barad, N. Gleicher, The impact of androgen metabolism and FMR1 genotypes on pregnancy potential in women with dehydroepiandrosterone (DHEA) supplementation. Hum. Reprod. 27, 3287–3293 (2012)CrossRef
17.
Zurück zum Zitat A.A. Bremer, Polycystic ovary syndrome in the pediatric population. Metabol. Syndr. Relat. Disord. 8, 375–394 (2010)CrossRef A.A. Bremer, Polycystic ovary syndrome in the pediatric population. Metabol. Syndr. Relat. Disord. 8, 375–394 (2010)CrossRef
18.
Zurück zum Zitat N. Gleicher, D.H. Barad, Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod. Biol. Endocrinol. 9, 67 (2011)CrossRef N. Gleicher, D.H. Barad, Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod. Biol. Endocrinol. 9, 67 (2011)CrossRef
19.
Zurück zum Zitat A. Ben-Meir, E. Burstein, A. Borrego-Alvarez, J. Chong, E. Wong, T. Yavorska, T. Naranian, M. Chi, Y. Wang, Y. Bentov, J. Alexis, J. Meriano, H.K. Sung, D.L. Gasser, K.H. Moley, S. Hekimi, R.F. Casper, A. Jurisicova, Coenzyme Q10 restores oocyte mitochondrial function and fertility during reproductive aging. Aging Cell. 14, 887–895 (2015)CrossRef A. Ben-Meir, E. Burstein, A. Borrego-Alvarez, J. Chong, E. Wong, T. Yavorska, T. Naranian, M. Chi, Y. Wang, Y. Bentov, J. Alexis, J. Meriano, H.K. Sung, D.L. Gasser, K.H. Moley, S. Hekimi, R.F. Casper, A. Jurisicova, Coenzyme Q10 restores oocyte mitochondrial function and fertility during reproductive aging. Aging Cell. 14, 887–895 (2015)CrossRef
20.
Zurück zum Zitat N. Gleicher, D. Barad, A. Weghofer, Functional autoantibodies, a new paradigm in autoimmunity? Autoimmune Rev. 7, 42–45 (2007)CrossRef N. Gleicher, D. Barad, A. Weghofer, Functional autoantibodies, a new paradigm in autoimmunity? Autoimmune Rev. 7, 42–45 (2007)CrossRef
21.
Zurück zum Zitat G.J. Pepe, A. Maniu, G. Aberdeen, T.J. Lynch, E.D. Albrecht, Estrogen regulation of adrenal cortical zone-specific development in the nonhuman primate impacts adrenal production of androgen and cortisol in response to ACTH in females in adulthood. Endocrinology 157, 1905–1913 (2016)CrossRef G.J. Pepe, A. Maniu, G. Aberdeen, T.J. Lynch, E.D. Albrecht, Estrogen regulation of adrenal cortical zone-specific development in the nonhuman primate impacts adrenal production of androgen and cortisol in response to ACTH in females in adulthood. Endocrinology 157, 1905–1913 (2016)CrossRef
22.
Zurück zum Zitat N. Gleicher, V.A. Kushnir, A. Weghofer, D.H. Barad, The importance of adrenal hypoandrogenism in infertile women with low functional ovarian reserve: a case study of associated adrenal insufficiency. Reprod. Biol. Endocrinol. 14, 23 (2016)CrossRef N. Gleicher, V.A. Kushnir, A. Weghofer, D.H. Barad, The importance of adrenal hypoandrogenism in infertile women with low functional ovarian reserve: a case study of associated adrenal insufficiency. Reprod. Biol. Endocrinol. 14, 23 (2016)CrossRef
23.
Zurück zum Zitat N. Gleicher, K. Seier, V.A. Kushnir, A. Weghofer, Y.-G. Wu, Q. Wang, D.F. Albertini, D.H. Barad, Association between peripheral androgens and cortisol in infertile women. J. Steroid Biochem. Mol. Biol. 158, 82–89 (2016)CrossRef N. Gleicher, K. Seier, V.A. Kushnir, A. Weghofer, Y.-G. Wu, Q. Wang, D.F. Albertini, D.H. Barad, Association between peripheral androgens and cortisol in infertile women. J. Steroid Biochem. Mol. Biol. 158, 82–89 (2016)CrossRef
24.
Zurück zum Zitat A. Fraissinet, G. Robin, P. Pigny, T. Lefebvre, S. Catteau-Jonard, D. Dewailly, Use of the serum antiMüllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypical classification of polycystic ovary syndrome. Hum. Reprod. 32(8), 1716–1722 (2017)CrossRef A. Fraissinet, G. Robin, P. Pigny, T. Lefebvre, S. Catteau-Jonard, D. Dewailly, Use of the serum antiMüllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypical classification of polycystic ovary syndrome. Hum. Reprod. 32(8), 1716–1722 (2017)CrossRef
25.
Zurück zum Zitat U. Ezeh, B.O. Yildiz, R. Azziz, Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary sundrome. J. Clin. Endocrinol. Metab. 98, E1088–E1096 (2013)CrossRef U. Ezeh, B.O. Yildiz, R. Azziz, Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary sundrome. J. Clin. Endocrinol. Metab. 98, E1088–E1096 (2013)CrossRef
26.
Zurück zum Zitat H. Prizant, N. Gleicher, A. Sen, Androgen actions in the ovary: balance is key. J. Endocrinol. 222, R141–R151 (2014)CrossRef H. Prizant, N. Gleicher, A. Sen, Androgen actions in the ovary: balance is key. J. Endocrinol. 222, R141–R151 (2014)CrossRef
27.
Zurück zum Zitat S. Garelli, S. Masiero, M. Plebani, S. Chen, J. Furmaniak, D. Armanini, C. Betterle, High prevalence of chronic thyroiditis in patients with polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 169, 248–251 (2013)CrossRef S. Garelli, S. Masiero, M. Plebani, S. Chen, J. Furmaniak, D. Armanini, C. Betterle, High prevalence of chronic thyroiditis in patients with polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 169, 248–251 (2013)CrossRef
28.
Zurück zum Zitat Y. Çakiroglu, F. Vural, B. Vural, 2016 The inflammatory markers in polycystic ovary syndrome: association with obesity and IVF outcomes. J. Endocrinol. Invest. 39, 899–907 (2016)CrossRef Y. Çakiroglu, F. Vural, B. Vural, 2016 The inflammatory markers in polycystic ovary syndrome: association with obesity and IVF outcomes. J. Endocrinol. Invest. 39, 899–907 (2016)CrossRef
29.
Zurück zum Zitat M.L. Pan, L.R. Hen, H.M. Tsao, K.H. Chen, Polycystic ovary syndrome and the risk of subsequent primary ovarian insufficiency: a nationwide population-based study. Menopause 24(7), 803–809 (2017)CrossRef M.L. Pan, L.R. Hen, H.M. Tsao, K.H. Chen, Polycystic ovary syndrome and the risk of subsequent primary ovarian insufficiency: a nationwide population-based study. Menopause 24(7), 803–809 (2017)CrossRef
Metadaten
Titel
Suspected ontogeny of a recently described hypo-androgenic PCOS-like phenotype with advancing age
verfasst von
Norbert Gleicher
Vitaly A. Kushnir
Sarah K. Darmon
Qi Wang
Lin Zhang
David F. Albertini
David H. Barad
Publikationsdatum
06.01.2018
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2018
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1498-8

Weitere Artikel der Ausgabe 3/2018

Endocrine 3/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.